Takeaway

• Tumour mutational burden (TMB) can accurately predict response to treatment with immune checkpoint inhibitors (ICIs) for female, but not for male melanoma patients.
• This sex bias may also be present in patients with glioblastoma and cancers of unknown primary (CUP).
• Clinicians should be aware of this potential bias.

Why...